Ultrapotent neutralizing antibodies against SARS-CoV-2 with a high degree of mutation resistance.
Zou J, Li L, Zheng P, Liang W, Hu S, Zhou S, Wang Y, Zhao J, Yuan D, Liu L, Wu D, Xu M, Zhang F, Zhu M, Wu Z, Cao X, Ni M, Ling X, Wu Y, Kuang Z, Hu M, Li J, Li X, Guo X, Xu T, Jiang H, Gao C, Yu M, Liu J, Zhong N, Zhou J, Huang JA, Jin T, He J.
Zou J, et al. Among authors: huang ja.
J Clin Invest. 2022 Feb 15;132(4):e154987. doi: 10.1172/JCI154987.
J Clin Invest. 2022.
PMID: 35108220
Free PMC article.